CTRI/2018/07/014716招募中未知
enalidomide as maintenance therapy in Chronic Lymphocytic Leukemia â?? A randomized open label study
试验速览
- 阶段
- 未知
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Newly diagnosed cases of Chronic Lymphocytic Leukemia (International workshop on Chronic lymphocytic leukemia guidelines for the diagnosis and treatment of CLL) who have achieved at least a partial response (IWCLL guidelines) following completion (minimum 3 cycles) of first line therapy and have completed treatment at least 8 weeks and not more than 6 months prior to randomisation.
- •2.Patients of CLL who have relapsed after prior therapy and have achieved at least a partial response (IWCLL guidelines for the diagnosis and treatment of CLL) following completion (minimum 3 cycles) of second or third line therapy. Treatment should have been completed at least 8 weeks and not more than 6 months prior to randomisation.
- •3. Able to understand and provide an informed signed consent.
- •4. ECOG performance status must be less than or equal to 2
排除标准
- •1. Active infection
- •2. Renal failure
- •3. Venous thromboembolism
- •4. Disease transformation (Richterâ??s transformation, Prolymphocytic leukemia)
- •5. Grade 2 or more neuropathy
研究者
相似试验
进行中（未招募）
不适用
enalidomide maintenance therapy in patients with MDS or AML with cytogenetic abnormalities involving monosomy 5 or del5q after allogeneic hematopoietic stem cell transplantation (HSCT) - LENAMAINT TRIApatients with MDS or AML with cytogenetic abnormalities involving monosomy 5 or del5q after allogeneic hematopoietic stem cell transplantationEUCTR2007-002433-37-DETechnische Universität Dresden
招募中
不适用
Consolidation treatment of Lenalidomide for patients with adult T-cell leukemia/lymphoma ineligible for hematopoietic stem cell transplant.JPRN-UMIN000030095orth Japan Hematology Study Group15
终止
2 期
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT01465230Yale University2
已完成
1 期
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)Leukemia, Lymphocytic, Chronic, B-CellNCT01373229David Rizzieri, MD21
已完成
2 期
enalidomide maintenance combined with Bortezomib following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years.Kahlers disease10035227multiple myelomaNL-OMON35414HOVO80